Business Type | Exporter, Supplier, Retailer |
Strength | 2 Mg |
Packaging | Box |
Color | White |
Click to view more |
Product Details
COMPOSITION:
\\n
\\n
Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg
\\n
\\n
INDICATION:
\\n
\\n
LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
\\n
\\n
LuciTram is indicated, in combination with dabrafenib, for:
\\n
\\n
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
\\n
\\n
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.
\\n
\\n
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
\\n
\\n
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.COMPOSITION:
\\n
\\n
Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg
\\n
\\n
INDICATION:
\\n
\\n
LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
\\n
\\n
LuciTram is indicated, in combination with dabrafenib, for:
\\n
\\n
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
\\n
\\n
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.
\\n
\\n
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
\\n
\\n
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.COMPOSITION:
\\n
\\n
Each Tablet contains: 2.254 mg Trametinib dimethyl sulfoxide equivalent to Trametinib……………… 2mg
\\n
\\n
INDICATION:
\\n
\\n
LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
\\n
\\n
LuciTram is indicated, in combination with dabrafenib, for:
\\n
\\n
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
\\n
\\n
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations.
\\n
\\n
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
\\n
\\n
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
Hi! Simply click below and type your query.
Our experts will reply you very soon.